Literature DB >> 23618815

History of gene therapy.

Thomas Wirth1, Nigel Parker, Seppo Ylä-Herttuala.   

Abstract

Two decades after the initial gene therapy trials and more than 1700 approved clinical trials worldwide we not only have gained much new information and knowledge regarding gene therapy in general, but also learned to understand the concern that has persisted in society. Despite the setbacks gene therapy has faced, success stories have increasingly emerged. Examples for these are the positive recommendation for a gene therapy product (Glybera) by the EMA for approval in the European Union and the positive trials for the treatment of ADA deficiency, SCID-X1 and adrenoleukodystrophy. Nevertheless, our knowledge continues to grow and during the course of time more safety data has become available that helps us to develop better gene therapy approaches. Also, with the increased understanding of molecular medicine, we have been able to develop more specific and efficient gene transfer vectors which are now producing clinical results. In this review, we will take a historical view and highlight some of the milestones that had an important impact on the development of gene therapy. We will also discuss briefly the safety and ethical aspects of gene therapy and address some concerns that have been connected with gene therapy as an important therapeutic modality.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADA-SCID; CHMP; China's State Food and Drug Administration; Clinical trials; Committee on Human Medicinal Products; DHFR; DNA; E1; E1B 55K; EMA; Ethics; European Medicines Agency; FDA; GCV; GMP; Ganciclovir; Gene therapy; Good manufacturing practise; HAT medium; HGPRT; HSV-TK; Herpes simplex virus thymidine kinase; History; NeoR; Neomycin resistance gene; OTC; PEG-ADA; RAC; RNA; RSV; Recombinant DNA Advisory Committee; Rous sarcoma virus; SFDA; Safety; TALEN; TIL; UCLA; US Food and Drug Administration; University of California, Los Angeles; Viral vectors; ZFN; adenosine deaminase deficiency; adenoviral gene; cDNA; complementary DNA; deoxyribonucleic acid; dihydrofolate reductase; hypoxanthine and thymidine containing medium; hypoxanthine-guanine phosphoribosyl transferase; ornithine transcarbamylase; p53; polyethylene glycol adenine deaminase; protein 53, a tumour suppressor; ribonucleic acid; transcription activator-like effector nuclease; tumour-infiltrating lymphocyte; zinc finger nucleases

Mesh:

Substances:

Year:  2013        PMID: 23618815     DOI: 10.1016/j.gene.2013.03.137

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  105 in total

Review 1.  Human Germline Genome Editing.

Authors:  Kelly E Ormond; Douglas P Mortlock; Derek T Scholes; Yvonne Bombard; Lawrence C Brody; W Andrew Faucett; Nanibaa' A Garrison; Laura Hercher; Rosario Isasi; Anna Middleton; Kiran Musunuru; Daniel Shriner; Alice Virani; Caroline E Young
Journal:  Am J Hum Genet       Date:  2017-08-03       Impact factor: 11.025

2.  One-pot Synthesis of Functional Poly(amino ester sulfide)s and Utility in Delivering pDNA and siRNA.

Authors:  Yunfeng Yan; Lian Xue; Jason B Miller; Kejin Zhou; Petra Kos; Sussana Elkassih; Li Liu; Atsushi Nagai; Hu Xiong; Daniel J Siegwart
Journal:  Polymer (Guildf)       Date:  2015-08-18       Impact factor: 4.430

3.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

4.  Generation of a caged lentiviral vector through an unnatural amino acid for photo-switchable transduction.

Authors:  Yan Wang; Shuai Li; Zhenyu Tian; Jiaqi Sun; Shuobin Liang; Bo Zhang; Lu Bai; Yuanjie Zhang; Xueying Zhou; Sulong Xiao; Qiang Zhang; Lihe Zhang; Chuanling Zhang; Demin Zhou
Journal:  Nucleic Acids Res       Date:  2019-11-04       Impact factor: 16.971

Review 5.  Intratympanic Gene Delivery of Antimicrobial Molecules in Otitis Media.

Authors:  Sung K Moon; David J Lim
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

Review 6.  Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors.

Authors:  Devan L Puhl; Anthony R D'Amato; Ryan J Gilbert
Journal:  Brain Res Bull       Date:  2019-06-05       Impact factor: 4.077

Review 7.  Transfection by cationic gemini lipids and surfactants.

Authors:  M Damen; A J J Groenen; S F M van Dongen; R J M Nolte; B J Scholte; M C Feiters
Journal:  Medchemcomm       Date:  2018-07-17       Impact factor: 3.597

Review 8.  State-of-the-art human gene therapy: part I. Gene delivery technologies.

Authors:  Dan Wang; Guangping Gao
Journal:  Discov Med       Date:  2014 Jul-Aug       Impact factor: 2.970

Review 9.  Virus-Based Nanoparticles as Versatile Nanomachines.

Authors:  Kristopher J Koudelka; Andrzej S Pitek; Marianne Manchester; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2015-09-25       Impact factor: 10.431

Review 10.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.